Skip to main content


Table 2 Cellular therapies

From: Novel and emerging therapies for B cell lymphoma

Cellular therapyNPatient populationORRCRGrade 3 CRS/NTGrade 3 AERef
ET190L1-ArtemisTM Therapy21DLBCL, FL,MCL, SLL/CLL, splenic MZL52%24%NoneLymphopenia, neutropenia, tremor, fever, rash[19]
Bispecific CAR (CD-19/CD-20)7DLBCL, ALL60% (DLBCL)40% (DLBCL)NoneNone[23]
Bispecific CAR (CD-19/CD-20)6DLBCL, FL, MCL,CLL50%33%NoneNone[24]
Bispecific CAR (CD-19/CD-22)6DLBCL, tFL, tMZL80%40%1 patient (20%)—NTNeutropenia, thrombocytopenia, hypophosphatemia, neurotoxicity[25]
Armored CAR T cells25DLBCL ,CLL, tFL, FL, WM72%57%2 patients (8%)—NTNeurotoxicity[26]
ACTR 0877r/r NHL50%33%NoneNeutropenia, leukopenia[27]
ACTR 7076DLBCL, FLNA50%NoneFebrile neutropenia[28]
  1. Abbreviations: N number of patients, ORR overall response rate, CR complete response rate, CRS cytokine release syndrome, NT neurotoxicity, AE adverse events, DLBCL diffuse large B cell lymphoma, CLL chronic leukemic leukemia, tFL transformed follicular lymphoma, FL follicular lymphoma, WM Waldenström’s macroglobulinemia, MCL mantle cell lymphoma, tMZL transformed marginal zone lymphoma, ALL acute lymphoblastic leukemia, NHL non-Hodgkin lymphoma, MZL marginal zone lymphoma, NA data unavailable